The In vitro and In vivo Development of a GLP-1 Stimulating Nutraceutical

Bitter hops extract is a novel gut-targeted plant-based nutraceutical for appetite control and long-term weight management, which was developed as part of a $20 million government research project and has received an additional $10 million in government and investor funding. A comprehensive research methodology comprised of hospital-based gut biopsy studies, robot-assisted high throughput screening, and clinical validation was undertaken, exemplifying how nutraceutical development should be conducted, and ultimately leading to the development of this highly bioactive ingredient that shares an overlapping mode of action with a new class of effective GLP-1-based anti-obesity drugs.
This presentation explores the scientific and clinical approach used to demonstrate the efficacy of bitter hops extract as a nutraceutical, with a stringent pharmacological approach, ensuring the clinical efficacy of this ingredient.
CHANGE TO HIGH QUALITY FOR BEST VIEWING EXPERIENCE